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Background: Infection with the human immunodeficiency virus
(HIV) and lung cancer represent two problems beginning in the 20th
century that are of epidemic proportions. By the end of the 20th
century, therapeutic programs of modest efficacy had been devel-
oped for both. Because both HIV infection and lung cancer are
common, it is not surprising that a number of patients would be
afflicted with both diseases simultaneously. There is a very limited
literature regarding the treatment and outcome of patients with both
diseases, particularly since the advent of highly active antiretroviral
therapy (HAART) for HIV infection.
Methods: We retrospectively reviewed our tumor registry to ascer-
tain cases with concurrent lung cancer and HIV diagnoses since
1996, at the advent of HAART. Twenty-nine patients were identified
at the University of Maryland, and five additional cases from an
affiliated institution were identified.
Results: Thirty patients had non-small cell lung cancer, and four
patients had small cell lung cancer. Of the 30 patients with non-
small cell lung cancer, 27 had stage IIIb/IV disease and were
analyzed for outcome on the basis of CD4 counts and HAART
therapy. Patients with CD4 counts 200 or those on HAART had
numerically, though not statistically, superior survival. Patients were
able to receive standard chemotherapy regimens, and the overall
survival was 5.2 months.
Conclusions: This single-institution analysis appears to indicate that
there is an increasing incidence of patients with lung cancer and HIV
infection. Patients with advanced NSCLC who are HIV positive
with CD4 counts 200 can be treated with chemotherapy and
demonstrate survival comparable to that of patients without HIV
infection.
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Human immunodeficiency virus infection (HIV) and pri-mary lung cancer are two major contemporary epidem-
ics. It is estimated that in the year 2007, 213,380 patients will
be diagnosed with primary lung cancer and 160,390 will die
of the disease.1 Many carcinogens contribute to the develop-
ment of lung cancer, but cigarette smoking is overwhelm-
ingly the most important risk factor.
HIV infection and the acquired immunodeficiency syn-
drome (AIDS) increase the risk of opportunistic infections
and also non-Hodgkin’s lymphoma and Kaposi sarcoma.
These malignancies were later joined by invasive cervical
cancer as AIDS-defining malignancies.2 Other cancers that
occur excessively in HIV/AIDS patients include lung cancer,
Hodgkin’s disease, soft-tissue malignancies, penile cancer,
lip cancer, and testicular seminoma. Frish et al.3 reviewed
cancer and HIV registries of 11 geographic areas of the
United States and found that lung cancer is the most fre-
quently diagnosed non-AIDS defining cancer (from 302,834
patients with AIDS, 808 were diagnosed with lung cancer
between the year 1978 and 1996). Frish et al.3 also note that
lung cancer relative risk increases with the progression of the
disease from HIV status to the AIDS disease, which meets the
criteria of association with immunosuppression. The standard
risk ratio of lung cancer in HIV and AIDS patients diagnosed
between 1990 and 1995, compared with the risk among the
U.S. population, was 6.5.4
Most case reports and series of HIV/AIDS patients with
lung cancer reported in the literature were published before
the era of highly active antiretroviral therapy (HAART). This
multidrug approach has revolutionized the care of AIDS
patients since it entered general clinical practice in 1996.5
In 1984, Irwin et al.6 reported the first case of HIV and
lung cancer. In 1989, the Italian cooperative group on AIDS-
related tumor reported eight cases of lung cancer. The median
age was 34 years; three patients could not be treated, and four
patients died of progressive disease while receiving treat-
ment. Five of the eight patients had a limited disease at
diagnosis.7 Since then, additional series have been pub-
lished8–13 (Table 1). Though most of the patients were rela-
tively young at lung cancer diagnosis, few received treat-
ments that were generally considered effective for lung
cancer, and the prognosis was dismal (reported median sur-
vival was between 1 and 5 months). The largest series was
from the Italian cooperative group on AIDS and tumor; it
included 36 patients diagnosed with HIV and lung cancer
between the years 1986 and 1998. The median age was 38
years compared with 53 years for the control group (102
HIV-negative patients with age 60 years). Three patients
had only received HAART therapy. Thirty-one patients had
non-small cell lung cancer (NSCLC) and five patients had
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small cell lung cancer (SCLC). The median survival of the
total group was 5 months versus 10 months for the control
group (p  0.0001).13
One review of HIV patients with lung cancer diagnosed
after the HAART era was presented by Bower et al.14; from
8640 HIV-seropositive patients diagnosed since 1986, 11
patients had lung cancers (10 NSCLC and one SCLC). Nine
of those patients developed lung cancer in the post-HAART
era (1997–2001), and six patients received HAART therapy
before developing lung cancer (median, 2 years). All patients
had stage IIIB or stage IV disease. The overall survival was
4 months. The author noted that the incidence of HIV-related
lung cancer increased from 0.8 per 100,000 patient-years in
the pre-HAART era, which is similar to the age- and sex-
matched rate for the general population, to 6.7 per 100,000
patient-years in the post-HAART era.15
We retrospectively reviewed lung cancer patients with
an onset of disease after 1996 who had concomitant infection
with HIV, which might have been diagnosed either before or
simultaneously with lung cancer.
MATERIALS AND METHODS
The tumor registry at University of Maryland Medical
System was searched for patients with a diagnosis of primary
lung cancer who also had been diagnosed with HIV/AIDS
between 1996 and January 2003. We also searched the
medical records at an affiliate institution, Baltimore Veterans
Affairs Medical Center, for the years 2000 to 2003. Paper and
electronic charts were reviewed with special attention to
demographic data, HIV risk factors, smoking habits, comor-
bidities, dates of diagnosis for HIV and lung cancer, CD4
counts, cancer histology, performance status (PS), staging,
treatment modalities, and survival. Viral load data were not
available for much of this period and were not captured. For
patients who were lost to follow-up, dates of death were
collected by using the Social Security Web site and/or calling
the next of kin. Survival was calculated from the date of
diagnosis of lung carcinoma according to the product limit
method of Kaplan and Meier.16 Survival information of
patients who were lost to follow-up was censored. This study
was approved by the institutional review board of the Uni-
versity of Maryland.
RESULTS
Demographics
From January 1, 1996 to December 31, 2003, 2042
patients were seen with lung cancer at University of
Maryland; 29 patients (1.4%) had the diagnosis of HIV/
AIDS infection. From January 1, 2000 to December 31,
2003, 387 patients with lung cancer were seen at the
Veterans Affairs Medical Center in Baltimore; five (1.3%)
had HIV/AIDS. Patients’ demographic characteristics are
described in Table 2.
Sixty-eight percent of HIV-positive patients with lung
cancer were male. All patients were African Americans
except for one Caucasian. In comparison, 63% and 30% of all
lung cancer patients were male and African American, re-
spectively. For patients in the registry with available infor-
TABLE 1. Prior Reports
Reference
No. of
patients
Median
Age (yr)
Status of
HIV disease Histology
Median
Survival (mo)
Irwin et al.6 1 35 HIV NSCLC NS
Moser et al.8 1 65 AIDS SCLC NS
Nusbaum9 1 45 AIDS SCLC NS
Monfardini et al.7 8 34 HIV 2,AIDS 6 NSCLC 6, SCLC 2 NS
Braun14 6 NS NS NSCLC 5, SCLC 1 NS
Karp et al.10 8 40 (mean) AIDS 8 NSCLC 8 2.8 (mean)
Flores et al.11 19 47 HIV 5,AIDS14 NSCLC 17, SCLC 2 3
Alshafie et al.12 11 (1990–1994) 49.7 NA NSCL 11 3.8
Tirelli et al.13 36 (1986–1998) 38 HIV16,AIDS20 NSCLC 31, SCLC 5 5
NSCLC, non-small cell lung cancer; SCLC, small cancer cell lung cancer; NS, not stated.
TABLE 2. Demographics
Characteristic n (%)
Sex 34
Male 23 (68%)
Female 11 (32%)
Median age, years (range) 44 (34–77)
Race
African American 33 (97%)
Caucasian 1 (3%)
Tobacco use 34 (100%)
Packs per year, median (range) 25 (8–60)
NSCLC 30
IIB 1 (3%)
IIIA 2 (7%)
IIIB 11 (37%)
IV 16 (53%)
Extensive SCLC 4 (100%)
Performance status
1 18
2 11
3 5
NSCLC, non-small cell lung cancer; SCLC, small cancer cell lung cancer.
Journal of Thoracic Oncology • Volume 2, Number 4, April 2007 Lung Cancer in HIV-Infected Patients
Copyright © 2007 by the International Association for the Study of Lung Cancer 269
mation, 86% (19 of 22 patients) had previous history of
intravenous drug abuse. All patients were smokers, with an
average of 25 packs of cigarettes per year (range, 6–50
pack-years).
Thirty patients (88%) were diagnosed with NSCLC,
and four patients (12%) had SCLC. All of the patients with
SCLC had extensive-stage disease. In the NSCLC group,
three patients had stage I to stage IIIA disease, and 27
patients had stage IIIB or stage IV disease. Of the total group,
18 patients (53%) had a PS of 0 or 1 on the Zubrod scale,17
11 patients (32%) had a PS of 2, and five patients (15%) had
a PS of at least 3.
Twenty-seven patients were diagnosed with HIV or
AIDS at least 6 months before the lung cancer diagnosis was
made. For seven patients (20%), the diagnosis of HIV infec-
tion was made concurrently with the diagnosis of lung cancer.
Of the 91 African American patients younger the 60 years
diagnosed at the University of Maryland with advanced-stage
NSCLC during the same period, 21 (23%) were HIV positive.
The characteristics of the patients’ HIV infection and therapy
are described in Table 3.
Treatment and Outcome
The treatment and outcome of these patients is summa-
rized in Table 4. Eighteen patients (60%) were treated with
HAART at some point before lung cancer diagnosis. Dura-
tion of therapy could not be assessed for all of the patients
because some had received care at multiple institutions. All
SCLC patients received chemotherapy composed of cisplatin
and etoposide. Median survival was 7.2 months (5–11
months).
In the NSCLC group with stage IIIB or stage IV
disease, seven patients were too ill to be treated (median
survival was 2 months). Fourteen patients received chemo-
therapy (51%); 10 of these patients tolerated a two-drug
regimen that included a platinum agent. Five patients were
able to tolerate two or more lines of chemotherapy. Three
patients were treated with concurrent chemotherapy, and four
patients received a palliative dose of radiation therapy to a
metastatic site. The median survival of patients with stage
IIIB or stage IV NSCLC was 5.2 months (range, 1–16). For
this group, patients with absolute CD4 of at least 200 at
diagnosis (n  15) had a median survival of 11.5 months
compared with 3.4 months for patients with CD4 counts
below 200 (p  0.12), Figure 1. Similarly, there was a
numeric superiority for HAART versus no HAART (6.7
versus 2.8 months) in terms of median survival, although this
did not achieve statistical significance (p  0.55), Figure 2.
For the entire group, length of time from HIV diagnosis to
lung cancer diagnosis had a significant (p  0.001) positive
influence on survival.
DISCUSSION
This is one of the largest single-institution experiences
with HIV-positive lung cancer patients in the post-HAART
era. The number of HIV patients diagnosed with lung cancer
TABLE 4. Treatment and Outcome
Treatment Number Median Survival (mo)
All patients 34 8.2
Cancer therapy
Yes 25
No 5
NA 4
SCLC 4 7.2
Chemotherapy 4
NSCLC
Stage IIb 1
Stage IIIA 3
Stage IIIB/IV 27 5.2
Chemotherapy 12
Radiation alone 4
Concurrent chemoradiotherapy 3
No therapy 4
NA 4
NSCLC, non-small cell lung cancer; SCLC, small cancer cell lung cancer; NA, not
available.
FIGURE 1. Survival for stage III/IV NSCLC patients by CD4
count.
TABLE 3. HIV History and Characteristics
n (%)
Time in years from HIV infection to lung cancer
diagnosis (mean)
3.7  4.3; range:
0.3 to 13.5
Highly active antiretroviral therapy (before or
after lung cancer diagnosis)
Yes 17 (60)
No 12 (40)
NA 1
HIV status at lung cancer diagnosis
HIV 20 (60)
AIDS 13 (40)
NA 1
CD4 count
200 21 (62)
200 13 (38)
History of intravenous drug abuse
Yes 20 (59)
No 11 (32)
NA 2 (9)
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seems to be increasing. From the tumor registry at the
University of Maryland, we found only four lung cancer
patients with a diagnosis of HIV in the period of 1990 to
1996, and 29 patients in the period of 1996 to 2003 (1.4% of
lung cancer patients). This increase in the incidence is prob-
ably not related to changes in the incidence of HIV or lung
cancer but, rather, to the new therapeutic advances for HIV.
The age-adjusted death rate from AIDS declined by 48%
from 1996 to 1997.18 The natural history of HIV infection has
changed because of improvements to immune function and
prolonged survival.19,20 This decline in HIV mortality is
related to many factors other than a possible decrease in the
disease incidence, including improved prophylaxis for oppor-
tunistic infections and more aggressive viral therapy, which is
represented by the application of HAART in clinical practice.
There are several interesting epidemiologic factors in
the current report. The young age at lung cancer diagnoses
(44 years) is similar to that observed by others and is
consistent with the age affected by HIV. It may also be
related to an early starting age of smoking and chronic
dysfunction of the immune system.3 Another important ob-
servation is the high incidence of intravenous drug abuse as
a risk factor for HIV (86%). Serraino et al.21 have previously
described a 6.2-fold higher incidence of lung cancer in HIV
patients with history of intravenous drug abuse compared
with patients with history of homosexual activity. It is likely
that those who are intravenous drug abusers are also tobacco
users. A recent epidemiologic report from another institution
serving the same metropolitan area as the University of
Maryland found that there was a very high rate of smoking
(97%) in the HIV-positive population. They did not observe
the strong preponderance of African American males seen in
our study.22
The median survival (8 months) for all patients seems
to represent an improvement compared with the survival of
patients in the pre-HAART era (median survival, 1–5
months). The low incidence of cases at our institution before
1996 precluded a survival comparison based on pre– versus
post–HAART-era cases. In advanced stages of NSCLC
(stages IIIB and IV), patients with higher CD4 counts tended
to have a better survival then those with lower counts (11.4
versus 9 months, respectively). The length of time from HIV
infection to lung cancer diagnosis had a positive influence on
prognosis; this observation is related to the fact that patient
who had both diseases diagnosed in a shorter interval of time
is the one who had more advanced diseases that were ignored
by the patient because of lifestyle or health care access
difficulties.
There are several possible mechanisms by which HAART
therapy could improve survival. Better immune function could
potentially result in a less aggressive disease. Clearly, fewer
opportunistic infections, preservation of performance, and nutri-
tional status allowed patients to tolerate more active therapy than
in the past. In addition, advances made in supportive care,
opportunistic infection prophylaxis, and the use of new-genera-
tion chemotherapeutic agents have played a major role in the
management of this disease since 1996.
Patients with stage III/IV NSCLC were analyzed as a
group because this constituted a fairly homogenous cohort
and because the approach and outcomes of these patients with
standard treatment have been well described. The median
survival of 5.2 months for patients with advanced-stage
disease is comparable with that reported from our institution
for patients (n  20, MST  5.8 months) with a PS of 2 or
3 treated on a recent trial and is superior to the outcomes
reported for untreated patients in prior series.23 Nevertheless,
this outcome is clearly inferior to the results from standard
two-drug platinum-based chemotherapy at our institution in
patients (n  33, MST  9.3 months) with a PS of 0 or 1.24
The absence of a statistically significant difference in
survival detected between those patients with preserved CD4
counts (200) and those with CD4 200, and also between
HAART-treated and non–HAART-treated patients, is likely
to be the result of the small number of patients evaluated. In
addition, the number of patients was too small to perform a
multivariate analysis.
The high proportion of African American patients de-
serves comment. The University of Maryland and the Balti-
more Veterans Affairs Medical Center are located in Balti-
more, MD, a city with a predominantly African American
population. Nevertheless, the tumor registry at the University
of Maryland indicates that approximately 30% of all lung
cancer patients are African American. Therefore, it does not
seem that this demographic fact alone is sufficient to account
for the high prevalence of lung cancer among African Amer-
icans. One possible explanation is that the HIV-positive
population in Baltimore is cared for by the University of
Maryland infectious disease service and that referral patterns
could account for this finding.
CONCLUSION
Lung cancer patients with HIV infection have been
encountered more frequently since the advancement of
HAART, especially in the minority population.
HIV infection needs to be ruled out in every young
patient with lung cancer, even in the presence of obvious risk
factors such as smoking.
The major finding of this retrospective series is that
patients with advanced-stage NSCLC have a survival time
that approaches that of the HIV-negative lung cancer patient.
Though not achieving statistical significance, it seems that
those patients with preserved CD4 counts and/or on HAART
FIGURE 2. Survival for stage III/IV NSCLC patients by
HAART.
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have improved outcomes compared with those with more
compromised immune status. Therefore, those individuals
presenting with good performance status, an absence of
severe opportunistic infection, and preserved nutritional sta-
tus should be considered for active therapy of lung cancer.
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